Catalyst
Slingshot members are tracking this event:
Aimmune (AIMT) Expects to Begin Open-Label Rollover Trial From PALISADE in Q4 2016 Evaluating AR101 in Treatment of Peanut Allergies: Follow-on Study named ARC004
Do you think this event is important to the companies below? How will it affect their stock price?
| Related Companies | Importance
|
Impact on Stocks
|
||||
|---|---|---|---|---|---|---|
| AIMT |
|
|
||||
Slingshot Insights Explained
Catalyst Date
Occurred on:
Dec 08, 2016
Occurred Source:
https://clinicaltrials.gov/ct2/show/NCT02993107
Related Projects
-
Don’t see a project related to the catalyst you care about?
Related Keywords
Open-label Rollover Trial, Arc004, Phase 3 Palisade Trial, Ar101, Peanut Allergies
